Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

NCT01812603 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT01812603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01812603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2013
Completion date
June 30, 2016
Enrollment
6 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer